Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder.

Researchers gave minocycline or a placebo to teens and young adults with autism. The pill is an antibiotic that calms brain inflammation. Each teen took both the drug and the placebo for six weeks, but no one knew which was which. Doctors tracked safety and behavior scores throughout the crossover.

The drug caused no harm, but it also helped no more than the sugar pill. Every behavior score stayed flat across both phases. The team called the trial a safe dead end for this age group.

Dawson et al. (2000) ran the same double-blind crossover design with secretin and also saw zero benefit. The matching null results show that single-dose biomed shots or pills rarely move the needle.

Patra et al. (2019) found atomoxetine gives a small, real drop in parent-rated hyperactivity. That positive signal came from a classic parallel-group RCT, not a crossover, so the design difference may explain why atomoxetine edged ahead while minocycline did not.

Hudson et al. (2012) sifted 33 psychotropic RCTs and concluded only a handful have solid evidence. Minocycline now joins the long list of “tried but failed” agents that their review would have flagged.

You can now rule out minocycline when families ask about anti-inflammatory pills for autism. Use the time you save to discuss options with proven modest gains, like atomoxetine for ADHD-like symptoms, or simply stay the course with behavioral plans.